ArticleCureus2026
Triple Renal Pathology in a Patient With Myeloperoxidase-Associated Vasculitis, Diabetic Nephropathy, and Immunoglobulin A Nephropathy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapidly progressive glomerulonephritis (RPGN) is a nephrologic emergency often caused by antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. While superimposed diabetic nephropathy can alter the clinical baseline, the concurrent presentation of ANCA vasculitis, diabetic nephropathy, and immunoglobulin A (IgA) nephropathy is uncommon. We present a unique case of a triple-overlap renal pathology. A 56-year-old female patient with a history of type 2 diabetes mellitus presented with acute kidney injury (AKI) with a peak serum creatinine of 5.2 mg/dL, accompanied by macroscopic hematuria and nephrotic-range proteinuria (urine protein-to-creatinine ratio >16,000 mg/g). Serological workup revealed highly elevated myeloperoxidase (MPO) antibodies (677 AI). A renal biopsy confirmed three distinct pathologies: focal crescentic glomerulonephritis, nodular diabetic glomerulosclerosis (Class III), and mesangial IgA deposition. The patient received induction therapy with plasma exchange (PLEX), pulse-dose corticosteroids, and intravenous cyclophosphamide. Due to the cumulative toxicity profile of cyclophosphamide, she was transitioned to maintenance rituximab. To address the residual proteinuria driven by the concurrent diabetic and IgA-associated glomerular injury, sodium-glucose cotransporter-2 (SGLT2) inhibitors and angiotensin receptor blockers (ARBs) were added as supportive therapy. Over 14 months, her serum creatinine stabilized at 1.45 mg/dL, MPO titers decreased to 28 AI, and proteinuria improved to ~6,200 mg/g. This case highlights the critical importance of renal biopsy in diabetic patients presenting with atypical renal function decline or active urinary sediment. Furthermore, it demonstrates that a multimodal therapeutic approach is associated with substantial renal recovery in complex overlapping glomerular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.